<DOC>
	<DOCNO>NCT00687804</DOCNO>
	<brief_summary>CRFB002D2301 : The core study design confirm efficacy safety ranibizumab ( 0.5 mg ) adjunctive therapy add laser photocoagulation and/or mono-therapy patient visual impairment due diabetic macular edema . CRFB002D2301E1 : A 24 month open-label extension study participant complete 12 month core study evaluate long-term safety efficacy ranibizumab ( 0.5 mg ) symptomatic treatment visual impairment due diabetic macular edema .</brief_summary>
	<brief_title>A 12 Month Core Study Assess Efficacy Safety Ranibizumab ( Intravitreal Injections ) Patients With Visual Impairment Due Diabetic Macular Edema 24 Month Open-label Extension Study</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Vision Disorders</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Visual acuity impairment Diabetic macular edema least one eye Type 1 type 2 diabetes mellitus Medication diabetes treatment must stable last 3 month Patients uncontrolled systemic ocular disease Laser photocoagulation study eye last 3 month Any history intraocular surgery study eye within past 3 month Blood pressure &gt; 160/100 mmHg Extension Completion Core Study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>DME</keyword>
	<keyword>Diabetic</keyword>
	<keyword>macula</keyword>
	<keyword>edema</keyword>
	<keyword>ranibizumab</keyword>
	<keyword>RESTORE</keyword>
</DOC>